Description
Cerebrolysin is a complex peptide preparation produced through standardized enzymatic hydrolysis of porcine brain tissue, yielding a defined mixture of low-molecular-weight neuropeptides, peptide fragments, and free amino acids. The preparation is one of the longest-studied brain-derived peptide complexes in neuropharmacology research, with research literature dating to the 1970s. Cerebrolysin has been investigated extensively in preclinical and clinical research literature for neurotrophic-like activity, with proposed mechanisms involving CNTF-domain and IGF-1-domain peptide fragments, BDNF expression endpoints, and mitochondrial function research in neuronal cell models. Russian, Austrian, German, and Chinese research groups have published Cerebrolysin research across stroke, traumatic brain injury, vascular dementia, and Alzheimer’s disease preclinical models. The compound has been identified as the source preparation from which several active peptide research analogs (including P21 / P021 from the Iqbal lab) were derived. This product is a GMP-manufactured lyophilized peptide hydrolysate preparation supplied for laboratory research applications.
Benefits (Research Focus)
• Neurotrophic peptide research — studied for CNTF-domain and IGF-1-domain peptide fragment activity in neuronal cell research
• BDNF pathway research — investigated for BDNF gene expression endpoints in neuronal cell research models
• Hippocampal neurogenesis research — explored for adult neurogenesis pathway markers in rodent research models
• Mitochondrial function research — examined for cellular bioenergetics endpoints in neuronal cell research
• Comparative peptide research — researched alongside derived analogs (P21 / P021) and other brain-derived peptide preparations
What Researchers Look At
• Adult hippocampal neurogenesis markers (BrdU, DCX, Ki67) in rodent research models
• BDNF gene and protein expression in neuronal cell research
• Mitochondrial markers and cellular bioenergetics endpoints
• Comparative pharmacology versus derived synthetic peptide analogs (P21 / P021)
• Peptide complex composition analysis and standardization across batches
Quick Specs
• Form: Lyophilized peptide complex (white to off-white powder)
• Net Peptide Content: 30 mg per vial
• Quantity: 1 vial
• Manufacturing: GMP-manufactured at supplier facility
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Composition: Mixed low-molecular-weight neuropeptides and free amino acids (peptide complex, not single-sequence)
• Identity: Peptide profile per supplier documentation
• Storage: Protect from light
Identity Basics
• Compound: Cerebrolysin (porcine brain peptide hydrolysate)
• Synonyms: Brain-derived peptide complex; porcine brain peptide hydrolysate; CNTF-domain containing peptide preparation
• Class: Complex peptide preparation; not a single-sequence peptide
• Source: Enzymatic hydrolysis of porcine brain tissue under GMP conditions
• Composition: Mixed neuropeptides and amino acid fragments — peptide profile per supplier documentation
• Approximate Formula: Variable (complex peptide mixture — no single molecular formula applies)
• CAS: 85182-97-4 (peptide complex category)
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Third-Party Testing
• Janoshik Does not test for Cerebrolysin
